Open AccessLiquid biopsies to distinguish malignant from benign pulmonary nodules
Author(s) -
Tao Rui,
Cao Wei,
Zhu Feng,
Nie Jinfu,
Wang Hongzhi,
Wang Lixiang,
Liu Pengcheng,
Chen Hailong,
Hong Bo,
Zhao Dahai
Publication year - 2021
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13982
Subject(s) - medicine , lung cancer , liquid biopsy , lung , pathology , pulmonary cancer , cancer , biomarker , biopsy , radiology , biochemistry , chemistry
Over the past decades, low‐dose computed tomography (LD‐CT) screening has been widely used for the early detection of lung cancer. Increasing numbers of indeterminate pulmonary nodules are now being discovered. However, it remains challenging to distinguish malignant from benign pulmonary nodules, especially those considered to be small or ground‐glass (GGN) nodules. Liquid biopsies have been successfully applied in the diagnosis of advanced lung cancer, and the potential value for early detection of lung cancer has made great progress. Recent studies have demonstrated the value of various blood‐based tumor biomarkers in determining the nature of pulmonary nodules, including cell‐free DNA (cfDNA), microRNAs (miRNAs), circulating tumor cells (CTCs) and tumor‐associated autoantibodies (AAbs). In this review, we summarize the latest progress of liquid biopsies, and their potential applications and challenges in the diagnosis of malignant pulmonary nodules.